Quarterly report · Q3
2160.TEDINET S100SA1Y
Period2023-01-01 → 2023-09-30
Filed2023-11-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 62
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥20.5bn | 2023-01-01 → 2023-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥6.5bn | 2023-07-01 → 2023-09-30d | Cons. | Revenue IFRS |
| Revenue | ¥17.4bn | 2022-01-01 → 2022-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥12.8bn | 2022-01-01 → 2022-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥4.6bn | 2022-07-01 → 2022-09-30d | Cons. | Revenue IFRS |
| Operating income | ¥6.8bn | 2023-01-01 → 2023-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.3bn | 2023-07-01 → 2023-09-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.5bn | 2022-01-01 → 2022-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥490m | 2022-07-01 → 2022-09-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥6.4bn | 2023-01-01 → 2023-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥1.3bn | 2023-07-01 → 2023-09-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥768m | 2022-01-01 → 2022-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥1.2bn | 2022-01-01 → 2022-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥433m | 2022-07-01 → 2022-09-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥2.2bn | 2023-01-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥554m | 2023-07-01 → 2023-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥389m | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥1.1bn | 2022-01-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥400m | 2022-07-01 → 2022-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥4.8bn | 2023-01-01 → 2023-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥790m | 2023-07-01 → 2023-09-30d | Cons. | Profit loss IFRS |
| Net income | −¥868m | 2022-01-01 → 2022-12-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥324m | 2022-01-01 → 2022-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥126m | 2022-07-01 → 2022-09-30d | Cons. | Profit loss IFRS |
| Total assets | ¥48.5bn | at 2023-09-30 | Cons. | Assets IFRS |
| Total assets | ¥33.9bn | at 2022-12-31 | Cons. | Assets IFRS |
| Total assets | ¥36.5bn | at 2022-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥21.9bn | at 2023-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥14.1bn | at 2022-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥26.6bn | at 2023-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥19.8bn | at 2022-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥22.0bn | at 2022-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥19.3bn | at 2021-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥24.2bn | at 2023-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥21.0bn | at 2022-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥22.9bn | at 2022-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥18.1bn | at 2023-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥11.0bn | at 2022-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥12.7bn | at 2022-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥14.4bn | at 2021-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥4.4bn | 2023-01-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥393m | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | −¥163m | 2022-01-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥3.7bn | 2023-01-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥4.1bn | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥2.9bn | 2022-01-01 → 2022-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥5.0bn | 2023-01-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥646m | 2022-01-01 → 2022-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥299m | 2022-01-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥46.61 | 2023-01-01 → 2023-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥11.68 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥8.19 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥22.67 | 2022-01-01 → 2022-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥8.42 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥46.13 | 2023-01-01 → 2023-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥11.33 | 2023-07-01 → 2023-09-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥8.11 | 2022-01-01 → 2022-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥22.46 | 2022-01-01 → 2022-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥8.28 | 2022-07-01 → 2022-09-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 50.0% | at 2023-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 61.8% | at 2022-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 62.8% | at 2022-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-09-30 | −¥24m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-09-30 | −¥24m |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | revenue | 2023-01-01 → 2023-09-30 | ¥2.3bn |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | revenue external | 2023-01-01 → 2023-09-30 | ¥2.3bn |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | revenue intersegment | 2023-01-01 → 2023-09-30 | ¥24m |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | segment profit | 2023-01-01 → 2023-09-30 | ¥888m |
| jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segment | revenue | 2023-01-01 → 2023-09-30 | ¥18.3bn |
| jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segment | revenue external | 2023-01-01 → 2023-09-30 | ¥18.3bn |
| jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segment | segment profit | 2023-01-01 → 2023-09-30 | ¥5.9bn |
| —segment total | revenue | 2023-01-01 → 2023-09-30 | ¥20.6bn |
| —segment total | revenue external | 2023-01-01 → 2023-09-30 | ¥20.5bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-09-30 | ¥24m |
| —segment total | segment profit | 2023-01-01 → 2023-09-30 | ¥6.8bn |
| Reconciling Itemsreconciling | revenue | 2022-01-01 → 2022-09-30 | −¥38m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-01-01 → 2022-09-30 | −¥38m |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | revenue | 2022-01-01 → 2022-09-30 | ¥1.8bn |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | revenue external | 2022-01-01 → 2022-09-30 | ¥1.7bn |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | revenue intersegment | 2022-01-01 → 2022-09-30 | ¥38m |
| jpcrp040300-q3r_E05712-000Medical Devicereportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥699m |
| jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segment | revenue | 2022-01-01 → 2022-09-30 | ¥11.0bn |
| jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segment | revenue external | 2022-01-01 → 2022-09-30 | ¥11.0bn |
| jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segment | segment profit | 2022-01-01 → 2022-09-30 | ¥796m |
| —segment total | revenue | 2022-01-01 → 2022-09-30 | ¥12.8bn |
| —segment total | revenue external | 2022-01-01 → 2022-09-30 | ¥12.8bn |
| —segment total | revenue intersegment | 2022-01-01 → 2022-09-30 | ¥38m |
| —segment total | segment profit | 2022-01-01 → 2022-09-30 | ¥1.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 682
| Item | Context | Value | Unit |
|---|---|---|---|
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)株式会社ジーエヌアイグループ | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)東京都中央区日本橋本町二丁目２番２号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Description of fact that consolidated financial statements have been prepared in accordance with IFRS financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Condensed quarterly consolidated statement of financial position IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Condensed year to quarter end consolidated statement of profit or loss IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Condensed quarter period consolidated statement of profit or loss IFRS (text) | CurrentQuarterDuration | Text · Plus | |
| Condensed year to quarter end consolidated statement of comprehensive income IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Condensed quarter period consolidated statement of comprehensive income IFRS (text) | CurrentQuarterDuration | Text · Plus | |
| Condensed quarterly consolidated statement of changes in equity IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Condensed quarterly consolidated statement of cash flows IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes reporting entity condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes basis of preparation condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant accounting policies condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant accounting estimates and judgements condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes fair value of financial instruments condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes earnings per share condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in ownership interest in subsidiaries condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes share capital and other equity items condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes purchase of intangible assets condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes subsequent events condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |